Rapamycin: San Antonio biotech firm seeks major funding infusion

Rapamycin Holdings Inc. has secured a pair of new licensing agreements from the University of Texas Health Science Center at San Antonio that could expand the marketability of its lead product candidate, eRapa-NP2g. In addition, the San Antonio-based drug development company will look to raise as much as $10 million in additional investor support to boost its commercialization efforts. The new licensing agreements are tied to potential human use of eRapa-NP2g. The first is related to the rejuvenation...